{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:21:37Z","timestamp":1791638497040,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Purinergic Signalling"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s11302-026-10175-1","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:46:50Z","timestamp":1784263610000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Is adenosine signalling entering the precision medicine era? From receptor pharmacology to patient stratification"],"prefix":"10.1007","volume":"22","author":[{"given":"Luca","family":"Antonioli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"Hask\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"9","key":"10175_CR1","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd2638","volume":"7","author":"G Hasko","year":"2008","unstructured":"Hasko G, Linden J, Cronstein B, Pacher P (2008) Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 7(9):759\u2013770. https:\/\/doi.org\/10.1038\/nrd2638","journal-title":"Nat Rev Drug Discov"},{"key":"10175_CR2","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3389\/fncel.2019.00124","volume":"13","author":"KA Jacobson","year":"2019","unstructured":"Jacobson KA, Tosh DK, Jain S, Gao ZG (2019) Historical and current adenosine receptor agonists in preclinical and clinical development. Front Cell Neurosci 13:124. https:\/\/doi.org\/10.3389\/fncel.2019.00124","journal-title":"Front Cell Neurosci"},{"key":"10175_CR3","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3389\/fimmu.2020.01310","volume":"11","author":"L Antonioli","year":"2020","unstructured":"Antonioli L, Fornai M, Pellegrini C, Bertani L, Nemeth ZH, Blandizzi C (2020) Inflammatory bowel diseases: it\u2019s time for the adenosine system. Front Immunol 11:1310. https:\/\/doi.org\/10.3389\/fimmu.2020.01310","journal-title":"Front Immunol"},{"issue":"3","key":"10175_CR4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1124\/pr.117.014878","volume":"71","author":"L Antonioli","year":"2019","unstructured":"Antonioli L, Blandizzi C, Pacher P, Hasko G (2019) The purinergic system as a pharmacological target for the treatment of immune-mediated inflammatory diseases. Pharmacol Rev 71(3):345\u2013382. https:\/\/doi.org\/10.1124\/pr.117.014878","journal-title":"Pharmacol Rev"},{"issue":"12","key":"10175_CR5","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/nrc3613","volume":"13","author":"L Antonioli","year":"2013","unstructured":"Antonioli L, Blandizzi C, Pacher P, Hasko G (2013) Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer 13(12):842\u2013857. https:\/\/doi.org\/10.1038\/nrc3613","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10175_CR6","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA (2023) The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41(3):374\u2013403. https:\/\/doi.org\/10.1016\/j.ccell.2023.02.016","journal-title":"Cancer Cell"},{"issue":"1","key":"10175_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/ALN.0000000000003841","volume":"135","author":"A Czopik","year":"2021","unstructured":"Czopik A, Yuan X, Evans SE, Eltzschig HK (2021) Targeting the hypoxia-adenosine link for controlling excessive inflammation. Anesthesiology 135(1):15\u201317. https:\/\/doi.org\/10.1097\/ALN.0000000000003841","journal-title":"Anesthesiology"},{"issue":"9","key":"10175_CR8","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.4049\/jimmunol.0901247","volume":"183","author":"A Ohta","year":"2009","unstructured":"Ohta A, Ohta A, Madasu M, Kini R, Subramanian M, Goel N, Sitkovsky M (2009) A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments. J Immunol 183(9):5487\u20135493. https:\/\/doi.org\/10.4049\/jimmunol.0901247","journal-title":"J Immunol"},{"key":"10175_CR9","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1146\/annurev.immunol.22.012703.104731","volume":"22","author":"MV Sitkovsky","year":"2004","unstructured":"Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C, Ohta A, Thiel M (2004) Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 22:657\u2013682. https:\/\/doi.org\/10.1146\/annurev.immunol.22.012703.104731","journal-title":"Annu Rev Immunol"},{"issue":"10","key":"10175_CR10","doi-asserted-by":"publisher","first-page":"4634","DOI":"10.4049\/jimmunol.157.10.4634","volume":"157","author":"G Hasko","year":"1996","unstructured":"Hasko G, Szabo C, Nemeth ZH, Kvetan V, Pastores SM, Vizi ES (1996) Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol 157(10):4634\u20134640","journal-title":"J Immunol"},{"issue":"13","key":"10175_CR11","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1096\/fj.99-0508com","volume":"14","author":"G Hasko","year":"2000","unstructured":"Hasko G, Kuhel DG, Chen JF, Schwarzschild MA, Deitch EA, Mabley JG, Marton A, Szabo C (2000) Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J 14(13):2065\u20132074. https:\/\/doi.org\/10.1096\/fj.99-0508com","journal-title":"FASEB J"},{"issue":"1","key":"10175_CR12","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1096\/fj.11-190934","volume":"26","author":"B Csoka","year":"2012","unstructured":"Csoka B, Selmeczy Z, Koscso B, Nemeth ZH, Pacher P, Murray PJ, Kepka-Lenhart D, Morris SM Jr., Gause WC, Leibovich SJ, Hasko G (2012) Adenosine promotes alternative macrophage activation via A2A and A2B receptors. FASEB J 26(1):376\u2013386. https:\/\/doi.org\/10.1096\/fj.11-190934","journal-title":"FASEB J"},{"issue":"1","key":"10175_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/pr.110.003285","volume":"63","author":"BB Fredholm","year":"2011","unstructured":"Fredholm BB, AP IJ, Jacobson KA, Linden J, Muller CE (2011) International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. Pharmacol Rev 63(1):1\u201334. https:\/\/doi.org\/10.1124\/pr.110.003285","journal-title":"Pharmacol Rev"},{"issue":"24","key":"10175_CR14","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1056\/NEJMra1205750","volume":"367","author":"HK Eltzschig","year":"2012","unstructured":"Eltzschig HK, Sitkovsky MV, Robson SC (2012) Purinergic signaling during inflammation. N Engl J Med 367(24):2322\u20132333. https:\/\/doi.org\/10.1056\/NEJMra1205750","journal-title":"N Engl J Med"},{"issue":"3","key":"10175_CR15","doi-asserted-by":"publisher","first-page":"897","DOI":"10.4049\/jimmunol.1701414","volume":"200","author":"JL Bowser","year":"2018","unstructured":"Bowser JL, Phan LH, Eltzschig HK (2018) The hypoxia-adenosine link during intestinal inflammation. J Immunol 200(3):897\u2013907. https:\/\/doi.org\/10.4049\/jimmunol.1701414","journal-title":"J Immunol"},{"key":"10175_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2025.102695","volume":"106","author":"P Rabbani","year":"2025","unstructured":"Rabbani P, Ramkhelawon B, Cronstein BN (2025) Adenosine metabolism and receptors in aging of the skin, musculoskeletal, immune and cardiovascular systems. Ageing Res Rev 106. https:\/\/doi.org\/10.1016\/j.arr.2025.102695","journal-title":"Ageing Res Rev"},{"issue":"6","key":"10175_CR17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.molmed.2013.03.005","volume":"19","author":"L Antonioli","year":"2013","unstructured":"Antonioli L, Pacher P, Vizi ES, Hasko G (2013) CD39 and CD73 in immunity and inflammation. Trends Mol Med 19(6):355\u2013367. https:\/\/doi.org\/10.1016\/j.molmed.2013.03.005","journal-title":"Trends Mol Med"},{"key":"10175_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.imlet.2018.04.006","volume":"205","author":"L Antonioli","year":"2019","unstructured":"Antonioli L, Fornai M, Blandizzi C, Pacher P, Hasko G (2019) Adenosine signaling and the immune system: when a lot could be too much. Immunol Lett 205:9\u201315. https:\/\/doi.org\/10.1016\/j.imlet.2018.04.006","journal-title":"Immunol Lett"},{"key":"10175_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2026.109011","volume":"281","author":"L Antonioli","year":"2026","unstructured":"Antonioli L, Valdiserra G, Pacher P, Robson SC, Hasko G (2026) Metabolic reprogramming and intracellular ATP homeostasis in immunity. Pharmacol Ther 281. https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109011","journal-title":"Pharmacol Ther"},{"issue":"4","key":"10175_CR20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/icb.2017.8","volume":"95","author":"D Allard","year":"2017","unstructured":"Allard D, Turcotte M, Stagg J (2017) Targeting A2 adenosine receptors in cancer. Immunol Cell Biol 95(4):333\u2013339. https:\/\/doi.org\/10.1038\/icb.2017.8","journal-title":"Immunol Cell Biol"},{"issue":"10","key":"10175_CR21","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41571-020-0382-2","volume":"17","author":"B Allard","year":"2020","unstructured":"Allard B, Allard D, Buisseret L, Stagg J (2020) The adenosine pathway in immuno-oncology. Nat Rev Clin Oncol 17(10):611\u2013629. https:\/\/doi.org\/10.1038\/s41571-020-0382-2","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10175_CR22","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ccell.2016.06.025","volume":"30","author":"A Young","year":"2016","unstructured":"Young A, Ngiow SF, Barkauskas DS, Sult E, Hay C, Blake SJ, Huang Q, Liu J, Takeda K, Teng MWL, Sachsenmeier K, Smyth MJ (2016) Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses. Cancer Cell 30(3):391\u2013403. https:\/\/doi.org\/10.1016\/j.ccell.2016.06.025","journal-title":"Cancer Cell"},{"issue":"3","key":"10175_CR23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.pharmthera.2008.08.010","volume":"120","author":"L Antonioli","year":"2008","unstructured":"Antonioli L, Fornai M, Colucci R, Ghisu N, Tuccori M, Del Tacca M, Blandizzi C (2008) Regulation of enteric functions by adenosine: pathophysiological and pharmacological implications. Pharmacol Ther 120(3):233\u2013253. https:\/\/doi.org\/10.1016\/j.pharmthera.2008.08.010","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10175_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.immuni.2017.06.020","volume":"47","author":"F Di Virgilio","year":"2017","unstructured":"Di Virgilio F, Dal Ben D, Sarti AC, Giuliani AL, Falzoni S (2017) The P2X7 receptor in infection and inflammation. Immunity 47(1):15\u201331. https:\/\/doi.org\/10.1016\/j.immuni.2017.06.020","journal-title":"Immunity"},{"issue":"1","key":"10175_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13059-020-1926-6","volume":"21","author":"D Lahnemann","year":"2020","unstructured":"Lahnemann D, Koster J, Szczurek E, McCarthy DJ, Hicks SC, Robinson MD, Vallejos CA, Campbell KR, Beerenwinkel N, Mahfouz A, Pinello L, Skums P, Stamatakis A, Attolini CS, Aparicio S, Baaijens J, Balvert M, Barbanson B, Cappuccio A, Corleone G, Dutilh BE, Florescu M, Guryev V, Holmer R, Jahn K, Lobo TJ, Keizer EM, Khatri I, Kielbasa SM, Korbel JO, Kozlov AM, Kuo TH, Lelieveldt BPF, Mandoiu II, Marioni JC, Marschall T, Molder F, Niknejad A, Raczkowska A, Reinders M, Ridder J, Saliba AE, Somarakis A, Stegle O, Theis FJ, Yang H, Zelikovsky A, McHardy AC, Raphael BJ, Shah SP, Schonhuth A (2020) Eleven grand challenges in single-cell data science. Genome Biol 21(1):31. https:\/\/doi.org\/10.1186\/s13059-020-1926-6","journal-title":"Genome Biol"},{"issue":"5","key":"10175_CR26","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41592-022-01409-2","volume":"19","author":"L Moses","year":"2022","unstructured":"Moses L, Pachter L (2022) Museum of spatial transcriptomics. Nat Methods 19(5):534\u2013546. https:\/\/doi.org\/10.1038\/s41592-022-01409-2","journal-title":"Nat Methods"},{"key":"10175_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2025.1616189","volume":"15","author":"Y Lin","year":"2025","unstructured":"Lin Y, Chen S, Che J, Sun M, Wang Y (2025) Multi-omics approaches for image classification in disease diagnosis. Front Cell Infect Microbiol 15. https:\/\/doi.org\/10.3389\/fcimb.2025.1616189","journal-title":"Front Cell Infect Microbiol"},{"key":"10175_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12103418","author":"I Rodriguez-Lago","year":"2023","unstructured":"Rodriguez-Lago I, Blackwell J, Mateos B, Marigorta UM, Barreiro-de Acosta M, Pollok R (2023) Recent advances and potential multi-omics approaches in the early phases of inflammatory bowel disease. J Clin Med. https:\/\/doi.org\/10.3390\/jcm12103418","journal-title":"J Clin Med"},{"key":"10175_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s11302-026-10165-3","author":"MP Abbracchio","year":"2026","unstructured":"Abbracchio MP, Damiani E (2026) Turning failure into success: how artificial intelligence can help personalize therapies and re-use patient data. Purinergic Signal. https:\/\/doi.org\/10.1007\/s11302-026-10165-3","journal-title":"Purinergic Signal"},{"issue":"5676","key":"10175_CR30","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497\u20131500. https:\/\/doi.org\/10.1126\/science.1099314","journal-title":"Science"},{"key":"10175_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29153501","author":"KN Venugopala","year":"2024","unstructured":"Venugopala KN, Buccioni M (2024) Current understanding of the role of adenosine receptors in cancer. Molecules. https:\/\/doi.org\/10.3390\/molecules29153501","journal-title":"Molecules"}],"container-title":["Purinergic Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-026-10175-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11302-026-10175-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-026-10175-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:10:52Z","timestamp":1787577052000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11302-026-10175-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10175"],"URL":"https:\/\/doi.org\/10.1007\/s11302-026-10175-1","relation":{},"ISSN":["1573-9538","1573-9546"],"issn-type":[{"value":"1573-9538","type":"print"},{"value":"1573-9546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"30 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}],"article-number":"63"}}